---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-26-000035"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:46:42.871132+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Caribou Q1 2026 rev flat at $2.4M; FDA aligns on pivotal trial for vispa-cel

## Summary
- FDA alignment on ANTLER-3 pivotal phase 3 trial for vispa-cel in 2L LBCL; primary endpoint PFS, crossover allowed.
- Cash and marketable securities $118.6M as of Mar 31, 2026; expected to fund into 2H 2027.
- R&D expenses down to $20.6M from $35.5M; G&A down to $8.1M from $9.7M YoY.
- CB-011 granted RMAT for r/r MM; enrollment ongoing, dose expansion data expected 2026.

## SEC filing metadata
- accession: 0001619856-26-000035
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/0001619856-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/crbu-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-26-000035
- JSON: https://secwatch.observer/filing/0001619856-26-000035.json
- Plain text: https://secwatch.observer/filing/0001619856-26-000035.txt

## Source-grounded claims
- claim_id: 4d11fbeb0529d3fa84017661bbeb26f3eeabe476
  claim: Caribou Biosciences, Inc. reported financial results for the first quarter of 2026.
  evidence_excerpt: reported financial results for the first quarter of 2026 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/0001619856-26-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.